Share This Author
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI.
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
- K. Pyörälä, T. Pedersen, J. Kjekshus, O. Faergeman, A. Olsson, G. Thorgeirsson
- MedicineDiabetes Care
- 1 April 1997
It is suggested that cholesterol lowering with simvastatin improves the prognosis of diabetic patients with CHD and the absolute clinical benefit achieved by cholesterol lowering may be greater in diabetic than in nondiabetic patients withCHD because diabetic patients have a higher absolute risk of recurrent CHD events and other atherosclerotic events.
Influence of Low High-Density Lipoprotein Cholesterol and Elevated Triglyceride on Coronary Heart Disease Events and Response to Simvastatin Therapy in 4S
- C. Ballantyne, A. Olsson, T. Cook, M. Mercuri, T. Pedersen, J. Kjekshus
- 18 December 2001
Patients with elevated HDL cholesterol, low HDL-C, and elevated triglycerides were more likely than patients with isolated LDL-C elevation to have other characteristics of the metabolic syndrome, had increased risk for CHD events on placebo, and received greater benefit with simvastatin therapy.
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease.
High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study
High-dose atorvastatin potentiated the decline in inflammation in patients with acute coronary syndromes and supports the value of early statin therapy in these patients.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study : A randomized controlled trial.